(IP) - Director General of Pardis Technology Park (PTP) for Communications and International Affairs pointed to Iran's ranking as one of the top 10 countries in the world regarding the diversity of pharmaceutical production.

Iran PressIran news: Pardis Technology Park, located in the northeast of Tehran, with an area of about 110 hectares, is known as Iran's most critical and largest technology park.

Amin Reza Khaleghian, Director General of Pardis Technology Park (PTP) for Communications and International Affairs, pointing to Iran's world ranking in terms of diversity of pharmaceutical production, stressed the production and export of knowledge-based companies, including radio and television transmitters, being produced under imposed sanctions, to 40 countries. 

Khaleghian pointed to PTP's role in paving the way for Iranian companies to attend exhibitions in joint pavilions, like in the past 15 years in Russia, Venezuela, Greece, Zimbabwe, and Kenya.

Referring to the agreement concluded with Venezuela for selling a thousand hemodialysis machines (HD), He announced sending the first shipment, where the rest will be sent over time.

He stressed the production of drugs to treat Multiple sclerosis (MS), a condition that can affect the brain and spinal cord, causing a wide range of potential symptoms, including problems with vision, arm or leg movement, sensation, or balance, in Iran as the sixth country in the world to produce them. 

He added that the treatment for Cutaneous leishmaniasis (CL), the most common form that causes skin lesions, mainly ulcers, on exposed parts of the body, is produced by one of the companies of PTP, and most of the medicine for CL treatment is exported.  

"We have cooperation with Uzbekistan, Kazakhstan, Russia, and some Arab and European countries," said Khaleghian in the end, stressing the international cooperative record of the PTP. 


Read More:

Iran uses gene transfer for Thalassemia patients' treatment